Episode Details

This episode discusses the serious implications of Lyme disease, especially cases that remain undiagnosed, highlighting its connection to autoimmune diseases and cancer.

We explore recent research, specifically a 2024 study that found "borrelia burgdorferi" DNA in invasive breast cancer cases, emphasizing the critical need for proper "Lyme disease testing". Understanding the role of the "immune system" and accurate "disease education" is vital for effective "cancer therapy" and overall "health" management.

🎯 What You’ll Learn in This Episode:
- Why Lyme disease is frequently missed
- What “chronic Lyme disease complex” really means
- How co-infections suppress immunity and drive inflammation
- The link between infections, autoimmunity, and cancer recurrence
- Why false-negative Lyme tests are common
- How neuroborreliosis affects the brain and nervous system
- Why infections must be treated before repair and recovery
- The right questions to ask your doctor about testing

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“You can’t rebuild the immune system until you remove what’s breaking it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493